Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK JACOBS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1073515201
CMS profile
320570
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$62.17

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $62.17 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Exact Sciences Corporation $40.30 2
Astellas Pharma Global Development $21.87 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK JACOBS

NPI 1073515201 · CMS profile ID 320570

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073515201?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK JACOBS, NPI 1073515201, CMS profile ID 320570. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073515201?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARK JACOBS, NPI 1073515201, CMS profile ID 320570. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073515201?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARK JACOBS, NPI 1073515201, CMS profile ID 320570, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1073515201?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $62.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exact Sciences Corporation $17.1009/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235653076 CMS
Exact Sciences Corporation $23.2004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235653072 CMS
Astellas Pharma Global Development $21.8702/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234126164 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $430.40 19
PY2021 $48.34 3
PY2022 $27.90 2
PY2023 $39.87 2
PY2024 $38.67 2
PY2025 $62.17 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $345,577.55 114
PY2024 Principal investigator $486,201.91 190
PY2023 Principal investigator $631,878.39 124
PY2022 Principal investigator $520,630.07 107
PY2021 Principal investigator $450,776.15 37
PY2020 Principal investigator $223,012.49 5
PY2019 Principal investigator $169,685.50 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

190 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Global Development $5,779.00 12/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125182
Principal investigator 1 Exeltis, USA Inc. $525.00 12/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149990125
Principal investigator 1 Astellas Pharma Global Development $797.00 12/10/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125180
Principal investigator 1 Astellas Pharma Global Development $686.00 12/03/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125184
Principal investigator 1 Astellas Pharma Global Development $5,844.00 11/26/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125108
Principal investigator 1 Exeltis, USA Inc. $550.00 11/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149989849
Principal investigator 1 Exeltis, USA Inc. $25.00 11/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149989853
Principal investigator 1 Exeltis, USA Inc. $250.00 11/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989794
Principal investigator 1 Exeltis, USA Inc. $250.00 11/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149989845
Principal investigator 1 Exeltis, USA Inc. $1,050.00 11/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989789
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1127535542
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1127535544
Principal investigator 1 Sumitomo Pharma America, Inc. $2,312.50 11/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425636
Principal investigator 1 Sumitomo Pharma America, Inc. $14,917.29 11/13/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425566
Principal investigator 1 Astellas Pharma Global Development $8,198.00 11/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125112
Principal investigator 1 Exeltis, USA Inc. $1,725.30 11/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149989778
Principal investigator 1 Sumitomo Pharma America, Inc. $2,965.49 11/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425562
Principal investigator 1 Sumitomo Pharma America, Inc. $2,251.71 11/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425564
Principal investigator 1 Exeltis, USA Inc. $387.00 11/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989612
Principal investigator 1 Organon LLC $250.00 11/06/2024 Non-covered Recipient Entity
TMC Life Research, Inc.
OG-6219-P001 No dispute reported 06/30/2026 1125523573
Principal investigator 1 Organon LLC $4,492.60 11/06/2024 Non-covered Recipient Entity
TMC Life Research, Inc.
OG-6219-P001 No dispute reported 06/30/2026 1125523575
Principal investigator 1 Sumitomo Pharma America, Inc. $304.80 11/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425560
Principal investigator 1 Astellas Pharma Global Development $7,122.00 11/05/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125110
Principal investigator 1 Astellas Pharma Global Development $1,464.00 10/30/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125178
Principal investigator 1 Sumitomo Pharma America, Inc. $2,488.25 10/29/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425634
Principal investigator 1 Astellas Pharma Global Development $8,839.00 10/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125168
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.75 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425620
Principal investigator 1 Sumitomo Pharma America, Inc. $2,876.00 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425622
Principal investigator 1 Sumitomo Pharma America, Inc. $4,140.00 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425624
Principal investigator 1 Sumitomo Pharma America, Inc. $6,077.25 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425626
Principal investigator 1 Sumitomo Pharma America, Inc. $19,739.21 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425628
Principal investigator 1 Sumitomo Pharma America, Inc. $1,559.25 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425630
Principal investigator 1 Sumitomo Pharma America, Inc. $933.74 10/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425632
Principal investigator 1 Astellas Pharma Global Development $845.00 10/15/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125166
Principal investigator 1 Exeltis, USA Inc. $4,624.87 10/15/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989465
Principal investigator 1 Astellas Pharma Global Development $1,432.00 10/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125164
Principal investigator 1 Astellas Pharma Global Development $31.00 10/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125176
Principal investigator 1 Sumitomo Pharma America, Inc. $604.52 10/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425556
Principal investigator 1 Sumitomo Pharma America, Inc. $3,002.28 10/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425558
Principal investigator 1 Astellas Pharma Global Development $1,077.00 10/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125170
Principal investigator 1 Astellas Pharma Global Development $343.00 10/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125172
Principal investigator 1 Astellas Pharma Global Development $2,606.00 10/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125174
Principal investigator 1 Exeltis, USA Inc. $1,050.00 10/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989233
Principal investigator 1 Exeltis, USA Inc. $250.00 10/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989237
Principal investigator 1 Exeltis, USA Inc. $525.00 10/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989241
Principal investigator 1 Exeltis, USA Inc. $1,575.00 10/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989245
Principal investigator 1 Sumitomo Pharma America, Inc. $563.00 10/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425618
Principal investigator 1 Exeltis, USA Inc. $500.00 10/03/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149989161
Principal investigator 1 Astellas Pharma Global Development $2,638.00 09/24/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125156
Principal investigator 1 Astellas Pharma Global Development $6,559.00 09/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125162
Principal investigator 1 Sumitomo Pharma America, Inc. $4,933.13 09/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425548
Principal investigator 1 Sumitomo Pharma America, Inc. $2,658.56 09/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425550
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 09/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425552
Principal investigator 1 Sumitomo Pharma America, Inc. $2,849.06 09/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425554
Principal investigator 1 Astellas Pharma Global Development $1,775.00 09/10/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125158
Principal investigator 1 Exeltis, USA Inc. $2,610.00 09/05/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149989003
Principal investigator 1 Sumitomo Pharma America, Inc. $635.00 09/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425538
Principal investigator 1 Sumitomo Pharma America, Inc. $4,652.01 09/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425540
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 09/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425542
Principal investigator 1 Sumitomo Pharma America, Inc. $127.00 09/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425544
Principal investigator 1 Sumitomo Pharma America, Inc. $1,950.72 09/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425546
Principal investigator 1 Astellas Pharma Global Development $2,654.00 09/03/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125160
Principal investigator 1 Sumitomo Pharma America, Inc. $3,766.82 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425520
Principal investigator 1 Sumitomo Pharma America, Inc. $1,797.05 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425522
Principal investigator 1 Sumitomo Pharma America, Inc. $254.00 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425524
Principal investigator 1 Sumitomo Pharma America, Inc. $11,528.30 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425526
Principal investigator 1 Sumitomo Pharma America, Inc. $1,012.19 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425528
Principal investigator 1 Sumitomo Pharma America, Inc. $381.00 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425530
Principal investigator 1 Sumitomo Pharma America, Inc. $4,931.41 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425532
Principal investigator 1 Sumitomo Pharma America, Inc. $1,308.10 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425534
Principal investigator 1 Sumitomo Pharma America, Inc. $3,079.75 08/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425536
Principal investigator 1 Astellas Pharma Global Development $2,347.00 08/27/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125148
Principal investigator 1 Astellas Pharma Global Development $2,552.00 08/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125152
Principal investigator 1 Sumitomo Pharma America, Inc. $2,401.00 08/15/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425614
Principal investigator 1 Sumitomo Pharma America, Inc. $1,235.75 08/15/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425616
Principal investigator 1 Exeltis, USA Inc. $400.00 08/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149988822
Principal investigator 1 Exeltis, USA Inc. $600.00 08/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988896
Principal investigator 1 Exeltis, USA Inc. $550.00 08/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988901
Principal investigator 1 Astellas Pharma Global Development $2,864.00 08/13/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125142
Principal investigator 1 Astellas Pharma Global Development $124.00 08/13/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125144
Principal investigator 1 Astellas Pharma Global Development $488.00 08/13/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125154
Principal investigator 1 Astellas Pharma Global Development $2,717.00 08/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125150
Principal investigator 1 Sumitomo Pharma America, Inc. $1,653.54 08/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425516
Principal investigator 1 Sumitomo Pharma America, Inc. $523.24 08/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425518
Principal investigator 1 Exeltis, USA Inc. $25.00 08/05/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988806
Principal investigator 1 Exeltis, USA Inc. $1,100.00 08/05/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988809
Principal investigator 1 Sumitomo Pharma America, Inc. $3,322.75 08/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425604
Principal investigator 1 Sumitomo Pharma America, Inc. $2,916.50 08/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425606
Principal investigator 1 Sumitomo Pharma America, Inc. $990.25 08/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425608
Principal investigator 1 Sumitomo Pharma America, Inc. $11,378.21 08/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425610
Principal investigator 1 Sumitomo Pharma America, Inc. $3,753.00 08/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425612
Principal investigator 1 Astellas Pharma Global Development $7,265.00 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125146
Principal investigator 1 Sumitomo Pharma America, Inc. $1,845.31 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425506
Principal investigator 1 Sumitomo Pharma America, Inc. $127.00 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425508
Principal investigator 1 Sumitomo Pharma America, Inc. $127.00 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425510
Principal investigator 1 Sumitomo Pharma America, Inc. $2,440.94 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425512
Principal investigator 1 Sumitomo Pharma America, Inc. $523.24 08/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425514
Principal investigator 1 Astellas Pharma Global Development $1,432.00 07/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125140
Principal investigator 1 Sumitomo Pharma America, Inc. $3,094.17 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425486
Principal investigator 1 Sumitomo Pharma America, Inc. $2,849.06 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425488
Principal investigator 1 Sumitomo Pharma America, Inc. $2,719.46 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425490
Principal investigator 1 Sumitomo Pharma America, Inc. $2,198.43 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425492
Principal investigator 1 Sumitomo Pharma America, Inc. $2,198.43 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425494
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425496
Principal investigator 1 Sumitomo Pharma America, Inc. $2,849.06 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425498
Principal investigator 1 Sumitomo Pharma America, Inc. $2,443.54 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425500
Principal investigator 1 Sumitomo Pharma America, Inc. $1,201.42 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425502
Principal investigator 1 Sumitomo Pharma America, Inc. $2,849.06 07/17/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425504
Principal investigator 1 Exeltis, USA Inc. $652.50 07/11/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149988358
Principal investigator 1 Exeltis, USA Inc. $3,792.60 07/11/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988462
Principal investigator 1 Sumitomo Pharma America, Inc. $854.71 06/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425482
Principal investigator 1 Sumitomo Pharma America, Inc. $261.62 06/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425484
Principal investigator 1 Sumitomo Pharma America, Inc. $2,196.75 06/20/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425602
Principal investigator 1 Astellas Pharma Global Development $1,705.00 06/18/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125136
Principal investigator 1 Sumitomo Pharma America, Inc. $22,644.73 06/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425480
Principal investigator 1 Sumitomo Pharma America, Inc. $2,014.22 06/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425474
Principal investigator 1 Sumitomo Pharma America, Inc. $642.62 06/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425476
Principal investigator 1 Sumitomo Pharma America, Inc. $127.00 06/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425478
Principal investigator 1 Astellas Pharma Global Development $343.00 06/11/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125134
Principal investigator 1 Exeltis, USA Inc. $835.20 06/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149988044
Principal investigator 1 Astellas Pharma Global Development $343.00 06/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125138
Principal investigator 1 Exeltis, USA Inc. $652.50 06/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987851
Principal investigator 1 Exeltis, USA Inc. $525.00 06/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987857
Principal investigator 1 Sumitomo Pharma America, Inc. $801.37 05/29/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425470
Principal investigator 1 Sumitomo Pharma America, Inc. $1,724.66 05/29/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425472
Principal investigator 1 Astellas Pharma Global Development $454.00 05/28/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125132
Principal investigator 1 Exeltis, USA Inc. $2,100.00 05/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987761
Principal investigator 1 Sumitomo Pharma America, Inc. $18,528.68 05/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425600
Principal investigator 1 Astellas Pharma Global Development $2,606.00 05/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125130
Principal investigator 1 Sumitomo Pharma America, Inc. $2,669.50 05/16/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425598
Principal investigator 1 Astellas Pharma Global Development $2,606.00 05/14/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125128
Principal investigator 1 Exeltis, USA Inc. $4,613.62 05/10/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987572
Principal investigator 1 Exeltis, USA Inc. $3,039.30 05/10/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987654
Principal investigator 1 Sumitomo Pharma America, Inc. $4,804.87 05/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425594
Principal investigator 1 Sumitomo Pharma America, Inc. $2,193.74 05/09/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425596
Principal investigator 1 Exeltis, USA Inc. $525.00 05/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987507
Principal investigator 1 Exeltis, USA Inc. $250.00 05/02/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987511
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 05/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425468
Principal investigator 1 Exeltis, USA Inc. $150.00 04/26/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987489
Principal investigator 1 Exeltis, USA Inc. $550.00 04/26/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987494
Principal investigator 1 Sumitomo Pharma America, Inc. $880.50 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425580
Principal investigator 1 Sumitomo Pharma America, Inc. $778.75 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425582
Principal investigator 1 Sumitomo Pharma America, Inc. $6,300.00 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425584
Principal investigator 1 Sumitomo Pharma America, Inc. $9,706.25 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425586
Principal investigator 1 Sumitomo Pharma America, Inc. $3,211.25 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425588
Principal investigator 1 Sumitomo Pharma America, Inc. $748.00 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425590
Principal investigator 1 Sumitomo Pharma America, Inc. $1,620.01 04/25/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425592
Principal investigator 1 Sumitomo Pharma America, Inc. $335.28 04/24/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425464
Principal investigator 1 Sumitomo Pharma America, Inc. $55.88 04/24/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425466
Principal investigator 1 Astellas Pharma Global Development $2,263.00 04/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125122
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 04/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425462
Principal investigator 1 Sumitomo Pharma America, Inc. $2,200.02 04/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425578
Principal investigator 1 Astellas Pharma Global Development $686.00 04/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125124
Principal investigator 1 Astellas Pharma Global Development $343.00 04/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125126
Principal investigator 1 Exeltis, USA Inc. $1,305.00 04/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149987125
Principal investigator 1 Exeltis, USA Inc. $847.80 04/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987199
Principal investigator 1 Exeltis, USA Inc. $250.00 04/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987065
Principal investigator 1 Exeltis, USA Inc. $600.00 04/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987084
Principal investigator 1 Exeltis, USA Inc. $4,400.00 04/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987113
Principal investigator 1 Exeltis, USA Inc. $1,100.00 04/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987117
Principal investigator 1 Exeltis, USA Inc. $450.00 04/01/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149987121
Principal investigator 1 Exeltis, USA Inc. $2,000.00 03/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986965
Principal investigator 1 Exeltis, USA Inc. $627.50 03/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986969
Principal investigator 1 Exeltis, USA Inc. $35.00 03/22/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986973
Principal investigator 1 Exeltis, USA Inc. $500.00 03/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149986921
Principal investigator 1 Exeltis, USA Inc. $125.00 03/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149986924
Principal investigator 1 Exeltis, USA Inc. $4,725.00 03/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149986929
Principal investigator 1 Astellas Pharma Global Development $343.00 03/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125120
Principal investigator 1 Exeltis, USA Inc. $2,750.00 03/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986879
Principal investigator 1 Exeltis, USA Inc. $1,650.00 03/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986883
Principal investigator 1 Exeltis, USA Inc. $500.00 03/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986908
Principal investigator 1 Exeltis, USA Inc. $550.00 03/19/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986912
Principal investigator 1 Astellas Pharma Global Development $6,468.00 03/12/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125118
Principal investigator 1 Exeltis, USA Inc. $2,610.00 03/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149986544
Principal investigator 1 Exeltis, USA Inc. $3,026.70 03/07/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986639
Principal investigator 1 Sumitomo Pharma America, Inc. $2,160.33 03/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425456
Principal investigator 1 Sumitomo Pharma America, Inc. $14,976.73 03/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425458
Principal investigator 1 Sumitomo Pharma America, Inc. $1,592.64 03/06/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1148425460
Principal investigator 1 Sumitomo Pharma America, Inc. $3,567.50 02/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425568
Principal investigator 1 Sumitomo Pharma America, Inc. $3,922.89 02/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425570
Principal investigator 1 Sumitomo Pharma America, Inc. $275.00 02/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425572
Principal investigator 1 Sumitomo Pharma America, Inc. $2,135.00 02/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425574
Principal investigator 1 Sumitomo Pharma America, Inc. $8,793.00 02/23/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY No dispute reported 06/30/2026 1148425576
Principal investigator 1 Astellas Pharma Global Development $1,920.00 02/21/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125116
Principal investigator 1 Exeltis, USA Inc. $1,100.00 02/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986315
Principal investigator 1 Exeltis, USA Inc. $175.00 02/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986319
Principal investigator 1 Exeltis, USA Inc. $1,387.80 02/08/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149986323
Principal investigator 1 Astellas Pharma Global Development $8,000.00 01/05/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms No dispute reported 06/30/2026 1134125114
Principal investigator 1 Exeltis, USA Inc. $1,661.62 01/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
LF11401 No dispute reported 06/30/2026 1149985698
Principal investigator 1 Exeltis, USA Inc. $7,326.00 01/04/2024 Non-covered Recipient Entity
TMC LIFE RESEARCH INC
CF13303 No dispute reported 06/30/2026 1149985710